Observational Study on the Treatment of Metastatic, Castration-Resistant Prostate Cancer with Olaparib + Abiraterone

Prostate cancer is a malignant tumor of the prostate characterized by the uncontrolled, malignant proliferation of prostate tissue. In its early stages, the disease is usually asymptomatic; in advanced stages, symptoms may include frequent or difficult urination, blood in the urine or semen, and pain in the pelvis or lower back. The cancer can also form metastases (distant spread of cancer cells to other organs). Various treatment strategies are available, which are selected based on the patient and the characteristics of the tumor. In many cases, the goal of primary treatment is to lower testosterone levels (hormone deprivation therapy), since prostate cancer cells generally grow in response to the hormone testosterone. Either surgical removal of the testicles or hormonal therapy is suitable for this purpose. If tumor growth is observed despite the reduction in testosterone levels, the cancer is referred to as castration-resistant prostate cancer. For adult patients with metastatic, castration-resistant prostate cancer who are not suitable candidates for chemotherapy, the combination therapy of olaparib plus abiraterone has already been approved. Olaparib is a poly-ADP-ribose polymerase (PARP) inhibitor that prevents the repair of DNA damage in cancer cells, leading to cancer cell death. Abiraterone is used as part of antihormonal therapy and inhibits the production of testosterone, thereby removing the stimulus for cancer cell growth.

The goal of this observational study is to collect treatment data on the combination therapy of olaparib plus abiraterone in the clinical care of patients. No new form of therapy is being investigated.

Men aged 18 and older with metastatic, castration-resistant prostate cancer are eligible to participate in this study.